Related references
Note: Only part of the references are listed.DNA damage repair as a target in pancreatic cancer: state-of-the-art and future perspectives
Lukas Perkhofer et al.
GUT (2021)
Synergistic targeting and resistance to PARP inhibition in DNA damage repair-deficient pancreatic cancer
Johann Gout et al.
GUT (2021)
Prognostic impact of CD73 expression and its relationship to PD-L1 in patients with radically treated pancreatic cancer
Kyosti Tahkola et al.
VIRCHOWS ARCHIV (2021)
Metformin inhibits pancreatic cancer metastasis caused by SMAD4 deficiency and consequent HNF4G upregulation
Chengcheng Wang et al.
PROTEIN & CELL (2021)
A first-in-man phase 1 study of the DNA-dependent protein kinase inhibitor peposertib (formerly M3814) in patients with advanced solid tumours
Mark T. J. van Bussel et al.
BRITISH JOURNAL OF CANCER (2021)
The Functional Crosstalk between Myeloid-Derived Suppressor Cells and Regulatory T Cells within the Immunosuppressive Tumor Microenvironment
Maximilian Haist et al.
CANCERS (2021)
Development of resistance to FAK inhibition in pancreatic cancer is linked to stromal depletion
Hong Jiang et al.
GUT (2020)
Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors
Geoffrey Shapiro et al.
INVESTIGATIONAL NEW DRUGS (2020)
CD40 Agonist Antibodies in Cancer Immunotherapy
Robert H. Vonderheide
ANNUAL REVIEW OF MEDICINE, VOL 71, 2020 (2020)
Development of 2 Bromodomain and Extraterminal Inhibitors With Distinct Pharmacokinetic and Pharmacodynamic Profiles for the Treatment of Advanced Malignancies
Gerald Falchook et al.
CLINICAL CANCER RESEARCH (2020)
Ipilimumab and Gemcitabine for Advanced Pancreatic Cancer: A Phase Ib Study
Suneel D. Kamath et al.
ONCOLOGIST (2020)
Prexasertib increases the sensitivity of pancreatic cancer cells to gemcitabine and S-1
Yoshihito Morimoto et al.
ONCOLOGY REPORTS (2020)
Phase 2 study of vismodegib, a hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinoma
Ana De Jesus-Acosta et al.
BRITISH JOURNAL OF CANCER (2020)
A case of malignant hyperlactaemic acidosis appearing upon treatment with the mono-carboxylase transporter 1 inhibitor AZD3965
Rosie McNeillis et al.
BRITISH JOURNAL OF CANCER (2020)
Cancer statistics, 2020
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
The ACSL3-LPIAT1 signaling drives prostaglandin synthesis in non-small cell lung cancer
Maria Saliakoura et al.
ONCOGENE (2020)
Macropinocytosis confers resistance to therapies targeting cancer anabolism
Vaishali Jayashankar et al.
NATURE COMMUNICATIONS (2020)
Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer
Michael Overman et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Senescence-Induced Vascular Remodeling Creates Therapeutic Vulnerabilities in Pancreas Cancer
Marcus Ruscetti et al.
CELL (2020)
A Randomized Phase II Preoperative Study of Autophagy Inhibition with High-Dose Hydroxychloroquine and Gemcitabine/Nab-Paclitaxel in Pancreatic Cancer Patients
Herbert J. Zeh et al.
CLINICAL CANCER RESEARCH (2020)
Sufficiency of CD40 activation and immune checkpoint blockade for T cell priming and tumor immunity
Alexander H. Morrison et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
Pharmacologic Inhibitor of DNA-PK, M3814, Potentiates Radiotherapy and Regresses Human Tumors in Mouse Models
Frank T. Zenke et al.
MOLECULAR CANCER THERAPEUTICS (2020)
Consensus guidelines for the definition, detection and interpretation of immunogenic cell death
Lorenzo Galluzzi et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
ATM-Deficient Cancers Provide New Opportunities for Precision Oncology
Nicholas R. Jette et al.
CANCERS (2020)
Editorial: Oncogenic RAS-Dependent Reprogramming of Cellular Plasticity
Georgia Konstantinidou et al.
FRONTIERS IN ONCOLOGY (2020)
Pancreatic cancer stroma: an update on therapeutic targeting strategies
Abdel N. Hosein et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2020)
Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Metastatic Pancreatic Cancer: ASCO Guideline Update
Davendra P. S. Sohal et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors
Timothy A. Yap et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
DNMT1 as a therapeutic target in pancreatic cancer: mechanisms and clinical implications
Kah Keng Wong
CELLULAR ONCOLOGY (2020)
A WEE1 family business: regulation of mitosis, cancer progression, and therapeutic target
Andrea Ghelli Luserna di Rora et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
PLCγ1 suppression promotes the adaptation of KRAS-mutant lung adenocarcinomas to hypoxia
Maria Saliakoura et al.
NATURE CELL BIOLOGY (2020)
ACSL3-PAI-1 signaling axis mediates tumor-stroma cross-talk promoting pancreatic cancer progression
Matteo Rossi Sebastiano et al.
SCIENCE ADVANCES (2020)
Clinical and immune responses to anti-CD3 x anti-EGFR bispecific antibody armed activated T cells (EGFR BATs) in pancreatic cancer patients
Lawrence G. Lum et al.
ONCOIMMUNOLOGY (2020)
Phase 1 Study of Molibresib (GSK525762), a Bromodomain and Extra-Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid Tumors
Sarina A. Piha-Paul et al.
JNCI CANCER SPECTRUM (2020)
Phase IB/II Randomized Study of FOLFIRINOX Plus Pegylated Recombinant Human Hyaluronidase Versus FOLFIRINOX Alone in Patients With Metastatic Pancreatic Adenocarcinoma: SWOG S1313
Ramesh K. Ramanathan et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer
Kirsten L. Bryant et al.
NATURE MEDICINE (2019)
Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers
Conan G. Kinsey et al.
NATURE MEDICINE (2019)
A Stromal Lysolipid-Autotaxin Signaling Axis Promotes Pancreatic Tumor Progression
Francesca R. Auciello et al.
CANCER DISCOVERY (2019)
Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study)
Dung T. Le et al.
CLINICAL CANCER RESEARCH (2019)
Effect of Gemcitabine and nab-Paclitaxel With or Without Hydroxychloroquine on Patients With Advanced Pancreatic Cancer A Phase 2 Randomized Clinical Trial
Thomas B. Karasic et al.
JAMA ONCOLOGY (2019)
Immunohistological analysis of pancreatic carcinoma after vaccination with survivin 2B peptide: Analysis of an autopsy series
Terufumi Kubo et al.
CANCER SCIENCE (2019)
Randomized phase II trial of survivin 2B peptide vaccination for patients with HLA-A24-positive pancreatic adenocarcinoma
Hiroaki Shima et al.
CANCER SCIENCE (2019)
Potentially Curable Pancreatic Adenocarcinoma: ASCO Clinical Practice Guideline Update
Alok A. Khorana et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer
Talia Golan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Radiation therapy for pancreatic adenocarcinoma, a treatment option that must be considered in the management of a devastating malignancy
William A. Hall et al.
RADIATION ONCOLOGY (2019)
Sequential combination of bortezomib and WEE1 inhibitor, MK-1775, induced apoptosis in multiple myeloma cell lines
Rebecca S. S. Barbosa et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2019)
Toward personalized TGFβ inhibition for pancreatic cancer
Ryan M. Carr et al.
EMBO MOLECULAR MEDICINE (2019)
Dose Escalation Trial of the Wee1 Inhibitor Adavosertib (AZD1775) in Combination With Gemcitabine and Radiation for Patients With Locally Advanced Pancreatic Cancer
Kyle C. Cuneo et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
ATM Dysfunction in Pancreatic Adenocarcinoma and Associated Therapeutic Implications
Samantha A. Armstrong et al.
MOLECULAR CANCER THERAPEUTICS (2019)
The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
Jude Canon et al.
NATURE (2019)
WEE1 Inhibition Enhances Anti-Apoptotic Dependency as a Result of Premature Mitotic Entry and DNA Damage
Mathilde Rikje Willemijn de Jong et al.
CANCERS (2019)
Safety and Efficacy Results of a Phase I, Open-Label Study of Concurrent and Delayed Nivolumab in Combination With nab-Paclitaxel and Carboplatin in Advanced Non-small Cell Lung Cancer
Jonathan W. Goldman et al.
FRONTIERS IN ONCOLOGY (2019)
Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma
Glen J. Weiss et al.
INVESTIGATIONAL NEW DRUGS (2018)
Focal adhesion kinase a potential therapeutic target for pancreatic cancer and malignant pleural mesothelioma
Rajani Kanteti et al.
CANCER BIOLOGY & THERAPY (2018)
Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor
Matthew R. Janes et al.
CELL (2018)
Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial
Gregory L. Beatty et al.
GASTROENTEROLOGY (2018)
Phase I/II trial of pimasertib plus gemcitabine in patients with metastatic pancreatic cancer
Eric Van Cutsem et al.
INTERNATIONAL JOURNAL OF CANCER (2018)
Phase Ib Trial With Birabresib, a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins, in Patients With Selected Advanced Solid Tumors
Jeremy Lewin et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
The ATR Inhibitor AZD6738 Synergizes with Gemcitabine In Vitro and In Vivo to Induce Pancreatic Ductal Adenocarcinoma Regression
Yann Wallez et al.
MOLECULAR CANCER THERAPEUTICS (2018)
The BET inhibitor I-BET762 inhibits pancreatic ductal adenocarcinoma cell proliferation and enhances the therapeutic effect of gemcitabine
Fang Xie et al.
SCIENTIFIC REPORTS (2018)
Targeting WEE1 to enhance conventional therapies for acute lymphoblastic leukemia
Andrea Ghelli Luserna Di Rora et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Targeting Defects in the Cellular DNA Damage Response for the Treatment of Pancreatic Ductal Adenocarcinoma
Anna Schmitt et al.
ONCOLOGY RESEARCH AND TREATMENT (2018)
Genomics-Driven Precision Medicine for Advanced Pancreatic Cancer: Early Results from the COMPASS Trial
Kyaw L. Aung et al.
CLINICAL CANCER RESEARCH (2018)
Pharmacological macrophage inhibition decreases metastasis formation in a genetic model of pancreatic cancer
Heidi Griesmann et al.
GUT (2017)
Direct evidence for cancer-cell-autonomous extracellular protein catabolism in pancreatic tumors
Shawn M. Davidson et al.
NATURE MEDICINE (2017)
Targeting DNA Repair in Cancer : Beyond PARP Inhibitors
Jessica S. Brown et al.
CANCER DISCOVERY (2017)
Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update
Alok A. Khorana et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
Ahmet Zehir et al.
NATURE MEDICINE (2017)
Emerging roles of the CXCL12/CXCR4 axis in pancreatic cancer progression and therapy
Richard L. Sleightholm et al.
PHARMACOLOGY & THERAPEUTICS (2017)
Combined treatment of pancreatic cancer xenograft with 90Y-ITGA6B4-mediated radioimmunotherapy and PI3K/mTOR inhibitor
Winn Aung et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2017)
Olaparib in combination with irinotecan, cisplatin, and mitomycin C in patients with advanced pancreatic cancer
Mark Yarchoan et al.
ONCOTARGET (2017)
Locally Advanced Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline Summary
Edward P. Balaban et al.
JOURNAL OF ONCOLOGY PRACTICE (2017)
Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients with locally advanced or metastatic pancreatic cancer: a multicenter, randomized phase IIb study
B. Schultheis et al.
ANNALS OF ONCOLOGY (2017)
Targeting ATR in cancer medicine
Raghav Sundar et al.
CURRENT PROBLEMS IN CANCER (2017)
A phase II study to evaluate LY2603618 in combination with gemcitabine in pancreatic cancer patients
Berta Laquente et al.
BMC CANCER (2017)
Prevalence of Pathogenic Mutations in Cancer Predisposition Genes among Pancreatic Cancer Patients
Chunling Hu et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2016)
Bruton Tyrosine Kinase-Dependent Immune Cell Cross-talk Drives Pancreas Cancer
Andrew J. Gunderson et al.
CANCER DISCOVERY (2016)
First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas
A. Patnaik et al.
ANNALS OF ONCOLOGY (2016)
Combination of the MEK inhibitor pimasertib with BTK or PI3K-delta inhibitors is active in preclinical models of aggressive lymphomas
E. Gaudio et al.
ANNALS OF ONCOLOGY (2016)
Metabolic scavenging by cancer cells: when the going gets tough, the tough keep eating
Evdokia Michalopoulou et al.
BRITISH JOURNAL OF CANCER (2016)
DNMT1 Inhibition Reprograms Pancreatic Cancer Stem Cells via Upregulation of the miR-17-92 Cluster
Sladjana Zagorac et al.
CANCER RESEARCH (2016)
Genetic Diversity of Pancreatic Ductal Adenocarcinoma and Opportunities for Precision Medicine
Erik S. Knudsen et al.
GASTROENTEROLOGY (2016)
Randomized, Prospective Evaluation Comparing Intensity of Lymphodepletion Before Adoptive Transfer of Tumor-Infiltrating Lymphocytes for Patients With Metastatic Melanoma
Stephanie L. Goff et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid Tumors
Suzanne Leijen et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Genomic analyses identify molecular subtypes of pancreatic cancer
Peter Bailey et al.
NATURE (2016)
DNAJA1 controls the fate of misfolded mutant p53 through the mevalonate pathway
Alejandro Parrales et al.
NATURE CELL BIOLOGY (2016)
Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy
Hong Jiang et al.
NATURE MEDICINE (2016)
T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer
Eric Tran et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Phase I trial of vorinostat added to chemoradiation with capecitabine in pancreatic cancer
Emily Chan et al.
RADIOTHERAPY AND ONCOLOGY (2016)
Obesity-Induced Inflammation and Desmoplasia Promote Pancreatic Cancer Progression and Resistance to Chemotherapy
Joao Incio et al.
CANCER DISCOVERY (2016)
Stromal remodeling by the BET bromodomain inhibitor JQ1 suppresses the progression of human pancreatic cancer
Keisuke Yamamoto et al.
ONCOTARGET (2016)
Fatty Acid Oxidation Mediated by Acyl-CoA Synthetase Long Chain 3 Is Required for Mutant KRAS Lung Tumorigenesis
Mahesh S. Padanad et al.
CELL REPORTS (2016)
Pancreatic cancer
Jorg Kleeff et al.
NATURE REVIEWS DISEASE PRIMERS (2016)
Phase I trial of a first-in-class ATR inhibitor VX-970 as monotherapy (mono) or in combination (combo) with carboplatin (CP) incorporating pharmacodynamics (PD) studies.
Brent O'Carrigan et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Phase I trial of first-in-class ATR inhibitor VX-970 in combination with gemcitabine (Gem) in advanced solid tumors (NCT02157792).
Elizabeth R. Plummer et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Phase I study of olaparib plus gemcitabine in patients with advanced solid tumours and comparison with gemcitabine alone in patients with locally advanced/metastatic pancreatic cancer
J. Bendell et al.
ANNALS OF ONCOLOGY (2015)
Genetic Events That Limit the Efficacy of MEK and RTK Inhibitor Therapies in a Mouse Model of KRAS-Driven Pancreatic Cancer
Piergiorgio Pettazzoni et al.
CANCER RESEARCH (2015)
Human Pancreatic Cancer Tumors Are Nutrient Poor and Tumor Cells Actively Scavenge Extracellular Protein
Jurre J. Kamphorst et al.
CANCER RESEARCH (2015)
First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014
Bristi Basu et al.
CLINICAL CANCER RESEARCH (2015)
A phase I trial of mFOLFOX6 combined with the oral PI3K inhibitor BKM120 in patients with advanced refractory solid tumors
Autumn J. McRee et al.
INVESTIGATIONAL NEW DRUGS (2015)
Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer
Daniel V. T. Catenacci et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Safety and Survival With GVAX Pancreas Prime and Listeria Monocytogenes-Expressing Mesothelin (CRS-207) Boost Vaccines for Metastatic Pancreatic Cancer
Dung T. Le et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation
Bella Kaufman et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Whole genomes redefine the mutational landscape of pancreatic cancer
Nicola Waddell et al.
NATURE (2015)
BRD4 promotes pancreatic ductal adenocarcinoma cell proliferation and enhances gemcitabine resistance
Yong-Hui Wang et al.
ONCOLOGY REPORTS (2015)
Ataxia-telangiectasia-Mutated Protein Kinase Levels Stratify Patients With Pancreatic Adenocarcinoma Into Prognostic Subgroups With Loss Being a Strong Indicator of Poor Survival
Carsten Kamphues et al.
PANCREAS (2015)
Loss of ATM accelerates pancreatic cancer formation and epithelial-mesenchymal transition
Ronan Russell et al.
NATURE COMMUNICATIONS (2015)
Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets
Agnieszka K. Witkiewicz et al.
NATURE COMMUNICATIONS (2015)
The oncogenic receptor ErbB2 modulates gemcitabine and irinotecan/SN-38 chemoresistance of human pancreatic cancer cells via hCNT1 transporter and multidrug-resistance associated protein MRP-2
Nicolas Skrypek et al.
ONCOTARGET (2015)
Messenger RNA-based therapeutics for the treatment of apoptosis-associated diseases
Akitsugu Matsui et al.
SCIENTIFIC REPORTS (2015)
A Phase Ib Dose-Escalation Study of the Oral Pan-PI3K Inhibitor Buparlisib (BKM120) in Combination with the Oral MEK1/2 Inhibitor Trametinib (GSK1120212) in Patients with Selected Advanced Solid Tumors
Philippe L. Bedard et al.
CLINICAL CANCER RESEARCH (2015)
Myc and Ras oncogenes engage different energy metabolism programs and evoke distinct patterns of oxidative and DNA replication stress
Apolinar Maya-Mendoza et al.
MOLECULAR ONCOLOGY (2015)
A regimen combining the Wee1 inhibitor AZD1775 with HDAC inhibitors targets human acute myeloid leukemia cells harboring various genetic mutations
L. Zhou et al.
LEUKEMIA (2015)
Identification of Weel as a novel therapeutic target for mutant RAS-driven acute leukemia and other malignancies
E. Weisberg et al.
LEUKEMIA (2015)
Receptor tyrosine kinases: Characterisation, mechanism of action and therapeutic interests for bone cancers
Aude I. Segaliny et al.
JOURNAL OF BONE ONCOLOGY (2015)
A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer
M. Aglietta et al.
ANNALS OF ONCOLOGY (2014)
Depletion of Carcinoma-Associated Fibroblasts and Fibrosis Induces Immunosuppression and Accelerates Pancreas Cancer with Reduced Survival
Berna C. Oezdemir et al.
CANCER CELL (2014)
Stromal Elements Act to Restrain, Rather Than Support, Pancreatic Ductal Adenocarcinoma
Andrew D. Rhim et al.
CANCER CELL (2014)
Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors
Edward Sausville et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2014)
Novel DNA methyltransferase-1 (DNMT1) depleting anticancer nucleosides, 4′-thio-2′-deoxycytidine and 5-aza-4′-thio-2′-deoxycytidine
Jaideep V. Thottassery et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2014)
Phase II clinical trial of ex vivo-expanded cytokine-induced killer cells therapy in advanced pancreatic cancer
Moon Jae Chung et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2014)
Collagen Signaling Enhances Tumor Progression after Anti-VEGF Therapy in a Murine Model of Pancreatic Ductal Adenocarcinoma
Kristina Y. Aguilera et al.
CANCER RESEARCH (2014)
CSF1/CSF1R Blockade Reprograms Tumor-Infiltrating Macrophages and Improves Response to T-cell Checkpoint Immunotherapy in Pancreatic Cancer Models
Yu Zhu et al.
CANCER RESEARCH (2014)
MiR-365 induces gemcitabine resistance in pancreatic cancer cells by targeting the adaptor protein SHC1 and pro-apoptotic regulator BAX
Shin Hamada et al.
CELLULAR SIGNALLING (2014)
Treatment with Chemotherapy and Dendritic Cells Pulsed with Multiple Wilms' Tumor 1 (WT1)-Specific MHC Class I/II-Restricted Epitopes for Pancreatic Cancer
Shigeo Koido et al.
CLINICAL CANCER RESEARCH (2014)
A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas
Jeffrey R. Infante et al.
EUROPEAN JOURNAL OF CANCER (2014)
BET Bromodomain Inhibitors Block Growth of Pancreatic Cancer Cells in Three-Dimensional Collagen
Vaibhav Sahai et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial
Gary Middleton et al.
LANCET ONCOLOGY (2014)
Remodelling the extracellular matrix in development and disease
Caroline Bonnans et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2014)
Pancreatic Adenocarcinoma
David P. Ryan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Macrophages mediate gemcitabine resistance of pancreatic adenocarcinoma by upregulating cytidine deaminase
N. Weizman et al.
ONCOGENE (2014)
Clinical impact of circulating miR-221 in plasma of patients with pancreatic cancer
T. Kawaguchi et al.
BRITISH JOURNAL OF CANCER (2013)
Diabetes and risk of pancreatic cancer: a pooled analysis from the pancreatic cancer cohort consortium
Joanne W. Elena et al.
CANCER CAUSES & CONTROL (2013)
A phase I dose-escalation trial of 2-deoxy-D-glucose alone or combined with docetaxel in patients with advanced solid tumors
Luis E. Raez et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
Phase I, dose-escalation study of AZD7762 alone and in combination with gemcitabine in Japanese patients with advanced solid tumours
Takashi Seto et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
Erlotinib Prolongs Survival in Pancreatic Cancer by Blocking Gemcitabine-Induced MAPK Signals
Koji Miyabayashi et al.
CANCER RESEARCH (2013)
Histone Lysine-Specific Methyltransferases and Demethylases in Carcinogenesis: New Targets for Cancer Therapy and Prevention
Xuejiao Tian et al.
CURRENT CANCER DRUG TARGETS (2013)
Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer
Michael A. Jacobetz et al.
GUT (2013)
Evaluation of Ipilimumab in Combination With Allogeneic Pancreatic Tumor Cells Transfected With a GM-CSF Gene in Previously Treated Pancreatic Cancer
Dung T. Le et al.
JOURNAL OF IMMUNOTHERAPY (2013)
Phase I Study of a Systemically Delivered p53 Nanoparticle in Advanced Solid Tumors
Neil Senzer et al.
MOLECULAR THERAPY (2013)
RHOA-FAK Is a Required Signaling Axis for the Maintenance of KRAS-Driven Lung Adenocarcinomas
Georgia Konstantinidou et al.
CANCER DISCOVERY (2013)
Suppression of Nucleotide Metabolism Underlies the Establishment and Maintenance of Oncogene-Induced Senescence
Katherine M. Aird et al.
CELL REPORTS (2013)
BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer
A. Goncalves et al.
ANNALS OF ONCOLOGY (2012)
Enzymatic Targeting of the Stroma Ablates Physical Barriers to Treatment of Pancreatic Ductal Adenocarcinoma
Paolo P. Provenzano et al.
CANCER CELL (2012)
Mutant p53: one name, many proteins
William A. Freed-Pastor et al.
GENES & DEVELOPMENT (2012)
Forced Mitotic Entry of S-Phase Cells as a Therapeutic Strategy Induced by Inhibition of WEE1
Marieke Aarts et al.
CANCER DISCOVERY (2012)
Targeting Mutated K-ras in Pancreatic Adenocarcinoma Using an Adjuvant Vaccine
Ghassan K. Abou-Alfa et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2011)
Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy
Steven A. Rosenberg et al.
CLINICAL CANCER RESEARCH (2011)
Detection of Differentially Expressed microRNAs in Serum of Pancreatic Ductal Adenocarcinoma Patients: miR-196a Could Be a Potential Marker for Poor Prognosis
Xiangyu Kong et al.
DIGESTIVE DISEASES AND SCIENCES (2011)
Pancreatic cancers require autophagy for tumor growth
Shenghong Yang et al.
GENES & DEVELOPMENT (2011)
Long-term follow-up of patients with resected pancreatic cancer following vaccination against mutant K-ras
Synne Weden et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
Anti-tumour/metastasis effects of the potassium-sparing diuretic amiloride: an orally active anti-cancer drug waiting for its call-of-duty?
Hayden Matthews et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study
Hedy L. Kindler et al.
LANCET ONCOLOGY (2011)
Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy
Eric A. Collisson et al.
NATURE MEDICINE (2011)
CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans
Gregory L. Beatty et al.
SCIENCE (2011)
MicroRNA-21 in Pancreatic Cancer: Correlation with Clinical Outcome and Pharmacologic Aspects Underlying Its Role in the Modulation of Gemcitabine Activity
Elisa Giovannetti et al.
CANCER RESEARCH (2010)
Mechanism of Radiosensitization by the Chk1/2 Inhibitor AZD7762 Involves Abrogation of the G2 Checkpoint and Inhibition of Homologous Recombinational DNA Repair
Meredith A. Morgan et al.
CANCER RESEARCH (2010)
Cell Signaling by Receptor Tyrosine Kinases
Mark A. Lemmon et al.
CELL (2010)
Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)
Hedy Lee Kindler et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
The role of autophagy in anticancer therapy: promises and uncertainties
M. P. Tschan et al.
JOURNAL OF INTERNAL MEDICINE (2010)
MicroRNA miR-155 is a biomarker of early pancreatic neoplasia
Nils Habbe et al.
CANCER BIOLOGY & THERAPY (2009)
Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis
John M. L. Ebos et al.
CANCER CELL (2009)
Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis
Marta Paez-Ribes et al.
CANCER CELL (2009)
MicroRNAs in Plasma of Pancreatic Ductal Adenocarcinoma Patients as Novel Blood-Based Biomarkers of Disease
Jin Wang et al.
CANCER PREVENTION RESEARCH (2009)
Dual Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Blockade Is an Effective Radiosensitizing Strategy for the Treatment of Non-Small Cell Lung Cancer Harboring K-RAS Mutations
Georgia Konstantinidou et al.
CANCER RESEARCH (2009)
Up-regulation of miR-200 and let-7 by Natural Agents Leads to the Reversal of Epithelial-to-Mesenchymal Transition in Gemcitabine-Resistant Pancreatic Cancer Cells
Yiwei Li et al.
CANCER RESEARCH (2009)
SMAD4 Gene Mutations Are Associated with Poor Prognosis in Pancreatic Cancer
Amanda Blackford et al.
CLINICAL CANCER RESEARCH (2009)
Natural killer cells: integrating diversity with function
Kuldeep Cheent et al.
IMMUNOLOGY (2009)
Phase III Trial of Bevacizumab in Combination With Gemcitabine and Erlotinib in Patients With Metastatic Pancreatic Cancer
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer
Kenneth P. Olive et al.
SCIENCE (2009)
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers
Jeffrey A. Engelman et al.
NATURE MEDICINE (2008)
Experimental validation of miRNA targets
Donald E. Kuhn et al.
METHODS (2008)
MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma
A. E. Szafranska et al.
ONCOGENE (2007)
Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer
Nabeel Bardeesy et al.
GENES & DEVELOPMENT (2006)
Gemcitabine plus CI-994 offers no advantage over gemcitabine alone in the treatment of patients with advanced pancreatic cancer: results of a phase II randomized, double-blind, placebo-controlled, multicenter study
D. A. Richards et al.
ANNALS OF ONCOLOGY (2006)
Effect of gemcitabine on immune cells in subjects with adenocarcinoma of the pancreas
JMD Plate et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2005)
A meta-analysis of obesity and the risk of pancreatic cancer
A Berrington de Gonzalez et al.
BRITISH JOURNAL OF CANCER (2003)
p16 inactivation in pancreatic intraepithelial neoplasias (PanINs) arising in patients with chronic pancreatitis
C Rosty et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2003)
Receptor tyrosine kinase signalling as a target for cancer intervention strategies
E Zwick et al.
ENDOCRINE-RELATED CANCER (2001)
Pancreatic tumors show high levels of hypoxia:: Regarding Koong et al. IJROBP 2000;48: 919-922
P Vaupel et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2001)
Activation of the HIF pathway in cancer
PH Maxwell et al.
CURRENT OPINION IN GENETICS & DEVELOPMENT (2001)
Intradermal ras peptide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant:: Clinical and immunological responses in patients with pancreatic adenocarcinoma
MK Gjertsen et al.
INTERNATIONAL JOURNAL OF CANCER (2001)
Share Paper
